\n
<\/p>\n
Douglas B. Given, a director at Arrowhead Pharmaceuticals, Inc. (NASDAQ:), reported selling shares of common stock valued at approximately $121,555, according to a recent SEC filing. The transactions occurred on December 16 and 17, with shares sold at prices ranging from $21.90 to $22.04. The stock has since declined to $20.36, with InvestingPro<\/a> analysis indicating the company is currently overvalued. With a market capitalization of $2.56 billion, Arrowhead faces some financial challenges, as highlighted by its “Weak” overall financial health score. Following these sales, Given holds 124,167 shares of the company. The sales were part of a pre-established 10b5-1 trading plan, which allows insiders to set up a schedule for selling stocks to avoid potential conflicts of interest. InvestingPro<\/a> data reveals that analysts maintain a bullish stance with price targets ranging from $23 to $80, despite the company currently burning through cash. Discover more insights and 10+ additional ProTips with an InvestingPro subscription, including exclusive access to the comprehensive Pro Research Report for ARWR.<\/p>\n In other recent news, Arrowhead Pharma has seen a significant boost in its financial prospects following a global license and collaboration agreement with Sarepta <\/span><\/span> <\/span><\/span> Therapeutics (NASDAQ:). The partnership, expected to close in 2025, includes a substantial upfront payment of $500 million and an additional $325 million through a common stock purchase. This influx of capital is anticipated to support Arrowhead’s financial and developmental goals, particularly its first RNA interference therapeutic, which is expected to launch in 2026 pending approval.<\/p>\n The company has also made considerable progress in its drug development pipeline. Arrowhead has filed a New Drug Application for plozasiran, a therapy targeting familial chylomicronemia syndrome, which could potentially lead to approval and launch in 2025 and 2026 respectively. Additionally, Arrowhead has filed Clinical Trial Applications for its obesity programs, ARO-INHBE and ARO-ALK7, with plans to initiate Phase 1\/2 studies in 2025.<\/p>\n Recent analyst notes reflect mixed sentiments. H.C. Wainwright has shown confidence in Arrowhead, raising the stock’s price target from $60.00 to $80.00, while Bernstein SocGen Group, Piper Sandler, and Citi have lowered their price targets. Despite the adjustments, all firms have maintained their respective ratings on the stock. These are the recent developments in Arrowhead Pharma’s operations.<\/p>\n This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n